实体瘤靶向药物的研究进展

发布时间：2018-06-23 04:19

本文选题：实体瘤 + 靶向药物　；参考：《中国药房》2017年08期

【摘要】：目的:了解实体瘤靶向药物的研究进展。方法:查阅近年来国内外相关文献,就实体瘤靶向药物的研究进行归纳和总结。结果:临床的实体瘤靶向药物主要分为单克隆抗体和酪氨酸激酶抑制剂(TKI)。单克隆抗体中的曲妥珠单抗针对乳腺癌能选择性与内表皮生长因子2(HER-2)基因调控的p185糖蛋白结合,阻滞表皮细胞生长因子与HER-2再结合,延缓癌细胞生长,但对心脏功能有一定影响;贝伐单抗通过特异性结合并阻滞血管内皮生长因子,抑制肿瘤血管生成,是用于晚期结直肠癌一线药物,辅助用于晚期结直肠癌、肺癌、卵巢癌的疗效均较好;帕尼单抗用于转移性结直肠癌,但易出现较严重的不良反应;凡德他尼用于甲状腺髓样癌;阿帕西普用于转移性结直肠癌,但应警惕其引起的严重不良反应;舍瑞替尼是治疗间变性淋巴瘤激酶阳性的晚期非小细胞肺癌(NSCLC)的高效靶向药物。TKI中的克唑替尼用于NSCLC患者疗效较好;维罗非尼用于黑色素瘤;维莫德吉用于晚期基底细胞癌;瑞戈非尼用于转移性结直肠癌;阿西替尼用于其他药物治疗无效的晚期肾细胞癌患者;卡博替尼用于不可手术切除的晚期局部或转移性甲状腺髓样癌。结论:靶向药物治疗实体瘤取得显著疗效的同时,其暴露的问题也在增多,需要开展大量的研究来推动和完善实体瘤的个体化、靶向治疗,提高其治疗效果和安全性。
[Abstract]:Objective: to investigate the research progress of solid tumor targeting drugs. Methods: the research on solid tumor targeting drugs was summarized and summarized by consulting the relevant literatures at home and abroad in recent years. Results: clinical solid tumor targeting drugs were mainly divided into monoclonal antibody and tyrosine kinase inhibitor (TKI). Tratozumab, a monoclonal antibody, can selectively bind to p185 glycoprotein regulated by internal epidermal growth factor 2 (HER-2) gene, block the rebinding of epidermal growth factor and HER-2, and delay the growth of breast cancer cells. Bevacizumab is a first-line drug used in advanced colorectal cancer, which is used as a first-line drug for advanced colorectal cancer, and can be used in advanced colorectal cancer, lung cancer, and lung cancer through specific binding and blocking of vascular endothelial growth factor. The efficacy of ovarian cancer is better; Paniumab is used for metastatic colorectal cancer, but it is prone to severe adverse reactions; Vandtamib is used for thyroid medullary carcinoma; apacip is used for metastatic colorectal cancer. However, severe adverse reactions should be observed. Seritinib is a highly effective target drug for advanced non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase-positive. The efficacy of cezolinib in the treatment of NSCLC is better, and that of Verofinil in melanoma is better than that in non-small cell lung cancer (NSCLC), and seritinib is a highly effective target drug for advanced non-small cell lung cancer (NSCLC). Vimodeg was used in advanced basal cell carcinoma, rigofinil in metastatic colorectal cancer, azetinib in patients with advanced renal cell carcinoma who had not been treated with other drugs. Carbotini is used for late or metastatic medullary thyroid carcinoma that is unresectable. Conclusion: with the significant curative effect of targeted drug therapy for solid tumor, the problems of its exposure are also increasing. It is necessary to carry out a lot of research to promote and perfect the individualization of solid tumor, and to improve the efficacy and safety of targeted therapy.
【作者单位】：荆州市第二人民医院药剂科;
【分类号】：R979.1

【相似文献】